NRPH

New River (NRPH)

New River Pharmaceuticals (MM)

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:NRPH

1 2 3 Next >>

Date	Time	Source	Headline	Symbol	Company
04/18/2007	4:41PM	PR Newswire (US)	HealthShares(TM) Announces Changes to the HealthShares(TM) Neuroscience and Composite Indices	NASDAQ:NRPH	New River Pharmaceuticals (MM)
04/03/2007	9:00AM	PR Newswire (US)	New River Pharmaceuticals Inc. Announces Convertibility of 3.50% Convertible Subordinated Notes Due 2013	NASDAQ:NRPH	New River Pharmaceuticals (MM)
03/19/2007	10:00AM	PR Newswire (US)	New River Announces Expiration of Hart-Scott-Rodino Waiting Period	NASDAQ:NRPH	New River Pharmaceuticals (MM)
03/13/2007	7:30PM	PR Newswire (US)	New River Pharmaceuticals Announces Year-End Results	NASDAQ:NRPH	New River Pharmaceuticals (MM)
02/23/2007	5:07PM	PR Newswire (US)	Shire and New River Pharmaceuticals Announce FDA Approval of the First and Only Stimulant Prodrug VYVANSE(TM) (lisdexamfetamine	NASDAQ:NRPH	New River Pharmaceuticals (MM)
02/20/2007	6:00AM	PR Newswire (US)	New River Pharmaceuticals to be Acquired by Shire plc for $64 per Share	NASDAQ:NRPH	New River Pharmaceuticals (MM)
02/05/2007	10:18AM	PR Newswire (US)	New River Pharmaceuticals to Present at 2007 Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Conference	NASDAQ:NRPH	New River Pharmaceuticals (MM)
01/25/2007	3:01PM	PR Newswire (US)	James Shaffer Joins New River Pharmaceuticals as Vice President, Sales and Marketing	NASDAQ:NRPH	New River Pharmaceuticals (MM)
12/21/2006	11:34PM	PR Newswire (US)	New River Pharmaceuticals and Shire Receive Approvable Letter for VYVANSE(TM) (lisdexamfetamine dimesylate) for the Treatment of	NASDAQ:NRPH	New River Pharmaceuticals (MM)
12/21/2006	11:34PM	PR Newswire (US)	New River Pharmaceuticals and Shire Receive Approvable Letter for VYVANSE(TM) (lisdexamfetamine dimesylate) for the Treatment of	NASDAQ:NRPH	New River Pharmaceuticals (MM)
11/07/2006	5:22PM	PR Newswire (US)	New River Pharmaceuticals Announces Third Quarter 2006 Results	NASDAQ:NRPH	New River Pharmaceuticals (MM)
10/30/2006	9:00AM	PR Newswire (US)	Interim Results of a Phase III Trial of Lisdexamfetamine Dimesylate (NRP104/LDX) in ADHD Presented at Major Scientific Meeting	NASDAQ:NRPH	New River Pharmaceuticals (MM)
10/13/2006	9:45AM	PR Newswire (US)	New River Pharmaceuticals Conducts End-of-Phase II Meeting with FDA for NRP290	NASDAQ:NRPH	New River Pharmaceuticals (MM)
10/06/2006	9:25PM	PR Newswire (US)	FDA Issues Approvable Letter for NRP104 (lisdexamfetamine dimesylate) for the Treatment of ADHD	NASDAQ:NRPH	New River Pharmaceuticals (MM)
10/06/2006	9:23PM	PR Newswire (US)	New River Pharmaceuticals Inc. Receives Approvable Letter for NRP104	NASDAQ:NRPH	New River Pharmaceuticals (MM)
10/03/2006	5:20PM	PR Newswire (US)	Dr. Garen Manvelian Joins New River Pharmaceuticals as Chief Medical Officer	NASDAQ:NRPH	New River Pharmaceuticals (MM)
09/12/2006	3:00PM	PR Newswire (US)	New River Pharmaceuticals Inc. Meets Enrollment in NRP104 Adult Phase III Study	NASDAQ:NRPH	New River Pharmaceuticals (MM)
09/08/2006	5:38PM	PR Newswire (US)	New River Pharmaceuticals to Present at the Bear Stearns 19th Annual Healthcare Conference	NASDAQ:NRPH	New River Pharmaceuticals (MM)
08/17/2006	6:03PM	PR Newswire (US)	New River Pharmaceuticals Names Dr. Samir Roy Vice President, Formulation and Manufacturing	NASDAQ:NRPH	New River Pharmaceuticals (MM)
08/08/2006	5:46PM	PR Newswire (US)	New River Pharmaceuticals Announces Second Quarter 2006 Results	NASDAQ:NRPH	New River Pharmaceuticals (MM)
07/25/2006	4:58PM	PR Newswire (US)	New River Pharmaceuticals Announces Exercise of Co-Promotion Option in the U.S. for NRP104	NASDAQ:NRPH	New River Pharmaceuticals (MM)
07/25/2006	12:57PM	PR Newswire (US)	New River Pharmaceuticals Closes Sale of $135,000,000 Convertible Subordinated Notes	NASDAQ:NRPH	New River Pharmaceuticals (MM)
07/24/2006	9:41AM	Business Wire	AMRI Announces Long-Term Manufacturing Agreement with New River Pharmaceuticals	NASDAQ:NRPH	New River Pharmaceuticals (MM)
07/19/2006	9:06PM	PR Newswire (US)	New River Pharmaceuticals Prices $125 Million Convertible Subordinated Notes; Company to Repurchase Up to $51 million in Common	NASDAQ:NRPH	New River Pharmaceuticals (MM)
07/18/2006	5:26PM	PR Newswire (US)	New River Pharmaceuticals Announces Proposal to Offer $125 Million Convertible Subordinated Notes; Company to Repurchase up to	NASDAQ:NRPH	New River Pharmaceuticals (MM)
06/30/2006	10:31AM	PR Newswire (US)	New River Pharmaceuticals Announces Filing of Investigational New Drug Application for NRP409	NASDAQ:NRPH	New River Pharmaceuticals (MM)
06/23/2006	12:52PM	PR Newswire (US)	New River Pharmaceuticals to Host Conference Call on A01, A02 and A03 Clinical Abuse Liability Studies of NRP104	NASDAQ:NRPH	New River Pharmaceuticals (MM)
06/20/2006	5:30PM	PR Newswire (US)	New River Pharmaceuticals Provides Detail on A02 Clinical Abuse Liability Study of NRP104	NASDAQ:NRPH	New River Pharmaceuticals (MM)
06/18/2006	5:45PM	PR Newswire (US)	New River Pharmaceuticals Provides Detail on A01 Clinical Abuse Liability Study and Announces Results from A03 Study	NASDAQ:NRPH	New River Pharmaceuticals (MM)
06/14/2006	9:01AM	PR Newswire (US)	New River Pharmaceuticals to Present Results from NRP104 Abuse Liability Studies	NASDAQ:NRPH	New River Pharmaceuticals (MM)